Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Reexamination Certificate
2006-05-02
2010-11-23
Lankford, Leon B (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
C514S130000, C514S079000
Reexamination Certificate
active
07838512
ABSTRACT:
Methods and compositions for enhancing cancer cell death using therapeutically effective amounts of DNA damaging agent(s) that act in combination to enhance cancer cell death, e.g., nucleic acid precursors, and protein tyrosine kinase inhibitors, e.g., that inhibit EGFR activity. The agents and inhibitors are administered in an amount effective to kill cancer cells, that is, the combined effect is sufficient so that cancer cell death is enhanced. If not administered at the same time, the DNA damaging agent(s) and tyrosine kinase inhibitors are administered close enough in time so they are still able to enhance cancer cell death. The methods and compositions are useful to treat neoplastic disease, e.g., pancreatic cancer.
REFERENCES:
patent: 4677063 (1987-06-01), Mark et al.
patent: 4764378 (1988-08-01), Keith et al.
patent: 4826853 (1989-05-01), Piwinski et al.
patent: 5073379 (1991-12-01), Klimesch et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5151423 (1992-09-01), Piwinski et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5262409 (1993-11-01), Margolis et al.
patent: 5393890 (1995-02-01), Syoji et al.
patent: 5416091 (1995-05-01), King
patent: 5457105 (1995-10-01), Barker
patent: 5464840 (1995-11-01), Ting et al.
patent: 5512293 (1996-04-01), Landrau et al.
patent: 5523095 (1996-06-01), Wilson et al.
patent: 5561117 (1996-10-01), Wong et al.
patent: 5595762 (1997-01-01), Derrieu et al.
patent: 5661152 (1997-08-01), Bishop et al.
patent: 5672611 (1997-09-01), Doll et al.
patent: 5677171 (1997-10-01), Hudziak et al.
patent: 5684013 (1997-11-01), Afonso et al.
patent: 5696121 (1997-12-01), Bishop et al.
patent: 5700806 (1997-12-01), Doll et al.
patent: 5703090 (1997-12-01), Afonso et al.
patent: 5712280 (1998-01-01), Doll et al.
patent: 5714609 (1998-02-01), Doll et al.
patent: 5719148 (1998-02-01), Bishop et al.
patent: 5721236 (1998-02-01), Bishop et al.
patent: 5728703 (1998-03-01), Bishop et al.
patent: 5807853 (1998-09-01), Bishop et al.
patent: 5852034 (1998-12-01), Njoroge et al.
patent: 5858411 (1999-01-01), Nakagami et al.
patent: 5861395 (1999-01-01), Taveras et al.
patent: 5874442 (1999-02-01), Doll et al.
patent: 5877177 (1999-03-01), Taveras et al.
patent: 5925639 (1999-07-01), Doll et al.
patent: 5939416 (1999-08-01), Rane et al.
patent: 5945429 (1999-08-01), Taveras et al.
patent: 5958890 (1999-09-01), Rane et al.
patent: 5958939 (1999-09-01), Afonso et al.
patent: 5958940 (1999-09-01), Rane et al.
patent: 5965570 (1999-10-01), Cooper et al.
patent: 5972381 (1999-10-01), Sangekar et al.
patent: 5972598 (1999-10-01), Chaudhary et al.
patent: 5985879 (1999-11-01), Taveras et al.
patent: 6030982 (2000-02-01), Njoroge et al.
patent: 6040305 (2000-03-01), Taveras et al.
patent: 6071907 (2000-06-01), Njoroge et al.
patent: 6316462 (2001-11-01), Bishop et al.
patent: 6524832 (2003-02-01), Kufe et al.
patent: 0 214 092 (1987-03-01), None
patent: 0 270 818 (1988-06-01), None
patent: 0 341 860 (1989-11-01), None
patent: 0 396 083 (1990-11-01), None
patent: 0 495 454 (1992-07-01), None
patent: 0 856 315 (1995-08-01), None
patent: 1 560 406 (1976-10-01), None
patent: 08048632 (1996-02-01), None
patent: WO 92/11034 (1991-12-01), None
patent: WO 94/06916 (1994-03-01), None
patent: WO 95/10515 (1995-04-01), None
patent: WO 95/10516 (1995-04-01), None
patent: WO 95/15949 (1995-06-01), None
patent: WO 96/30018 (1996-10-01), None
patent: WO 96/30362 (1996-10-01), None
patent: WO 96/30363 (1996-10-01), None
patent: WO 96/31477 (1996-10-01), None
patent: WO 96/31478 (1996-10-01), None
patent: WO 97/23478 (1997-07-01), None
patent: WO 97/36587 (1997-10-01), None
patent: WO 97/38664 (1997-10-01), None
patent: WO 97/38697 (1997-10-01), None
patent: WO 97/45412 (1997-12-01), None
patent: WO 98/00113 (1998-01-01), None
patent: WO 98/11091 (1998-03-01), None
patent: WO 98/35554 (1998-08-01), None
patent: WO 98/54966 (1998-12-01), None
patent: WO 99/31140 (1999-06-01), None
patent: WO 99/32118 (1999-07-01), None
Bailey et al., Cancer Chemother. Pharmacol. ,1992, vol. 30 p. 279-302.
Levitzki A., FASEB J, 1992, vol. 6, p. 3275-3282.
Baselga et al. , Journal of the National Cancer Institute, 1993, vol. 85, No. 16, p. 1327-1333.
Yoneda et al., Cancer Research, 1991, vol. 51, p. 4430-4435.
Capranico et al., Experimental cancer, 1985, Abstract.
Husain et al., Journal of Bacteriology, 1985, vol. 163, No. 3, p. 817-823.
Aboud Pirak et al., “Efficacy of Antibodies to Epidermal Growth Factor Receptor Against KB Carcinoma in Vitro and in Nude Mice,”J. Natl. Cancer Institute,80:1605-1611, 1988.
Aboud-Pirak et al., “Inhibition of human tumor growth in nude mice by a conjugate of doxorubicin with monoclonal antibodies to epidermal growth factor receptor,”Proc. Natl. Acad. Sci.USA, 86:3778-3781, 1989.
Baselga et al., “Antitumor Effects of Doxorubicin in Combustion With Anti-epidermal Growth Factor Receptor Monoclonal Antibodies,”J. Natl. Cancer Institute,85:1327-1333, 1993.
Fan et al., “Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies,”Cancer Res.,53:4322-4328, 1993.
Hurwitz et al., “A synergistic effect between anti-idiotype antibodies and anti-neoplastic drugs in the therapy of a murine B-cell tumor,”Int. J. Cancer,37:739-745, 1986.
Levitzki, “Tyrphostins—potential antiproliferative agents and novel molecular tools,”Biochem. Pharmacol.,40:913-918, 1990.
Nagane et al., “Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor,”J. Neurosurg.,95:472-479, 2001.
Novogrodsky et al., “Tyrphostin 4-nitrobenzylidene malononitrile reduces chemotherapy toxicity without impairing efficacy,”Cancer Res.,58:2397-2403, 1998.
Oude Weernink et al., “Inhibitors of Protein Tyrosine Phosphorylation Reduce the Proliferation of Two Human Glioma Cell Lines,”Neurosurgery,38:108-114, 1996.
Reddy et al., “Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor,”Cancer Res.,52:3636-3641, 1992.
Schechter et al., “Indirect immunotargeting of cis-Pt to human epidermoid carcinoma KB using the avidin-biotin system,”Int. J. Cancer,48:167-172, 1991.
Tsai et al., “Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells,”Cancer Res.,56:1068-1074, 1996.
Yoneda et al., “Dependence of a human squamous carcinoma and associated paraneoplastic syndromes on the epidermal growth factor receptor pathway in nude mice,”Cancer Res.,51:2438-2443, 1991.
Ciardiello et al., “Antitumor Effect and Potentiation of Cytotoxic Drugs Activity in Human Cancer Cells by ZD-1839 (Iressa), an Epidermal Growth Factor Receptor-selective Tyrosine Kinase Inhibitor,”Clin. Can. Res.,6: 2053-2063 (2000).
Davies et al., “Pharmacodynamic Separation of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy in Non-Small-Cell Lung Cancer,”Clin. Lung Can.,7(6): 385-388 (2006).
Erlichman et al., “The HER Tyrosine Kinase Inhibitor CI1033 Enhances Cytotoxicity of 7-Ethyl-10-hydroxycamptothecin and Topotecan by Inhibiting Breast Cancer Resistance Protein-mediated Drug Efflux,”Canc. Res.,61: 739-748 (2001).
Giaccone et al., “Gefitinib in Combination With Gemcitabine and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 1,”J. Clin. Onc.,22(5): 777-784 (2004).
Herbst et al., “Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial—INTACT 2,”J. Clin. Onc.,22(5):785-794 (2004).
Herbst et al., “TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non-Small-Cell Lung Cancer,”J. Clin. Onc.,23(25): 5892-5899 (200
Kufe Donald
Weichselbaum Ralph R.
Arch Development Corporation
Ariani Kade
Barnes & Thornburg LLP
Dana-Farber Cancer Institute
Lankford Leon B
LandOfFree
DNA damaging agents in combination with tyrosine kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA damaging agents in combination with tyrosine kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA damaging agents in combination with tyrosine kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252171